Clinical Effect of Entecavir Combined with Pegylated Interferons in Patients with Hepatitis B
- VernacularTitle:恩替卡韦联合聚乙二醇干扰素抗乙肝病毒疗效观察
- Author:
Yao XIAO
;
Jianqing WANG
;
Yawen ZHU
;
Jia LIU
- Keywords:
Entecavir;
Pegylated interferons;
Viral hepatitis;
Hepatitis B
- From:
China Pharmacist
2017;20(8):1420-1422
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical effect of entecavir combined with pegylated interferons in the patients with hepatitis B.Methods: Totally 72 patients with hepatitis B were randomly divided into the experimental group and the control group with 36 ones in each.The patients in the experimental group were treated with entecavir combined with pegylated interferons, and those in the control group were treated with entecavir.The clinical indicators in the two groups were detected and compared after the 24-week, 48-week and 6-month treatment.The adverse drug reactions in the two groups were recorded and compared.Results: After the 24-week treatment, the differences in the clinical indicators between the groups were not statistically significant (P >0.05).After the 48-week and 6-month treatment, the clinical indicators in the experimental group were obviously higher than those in the control group, and the differences were statistically significant (P <0.05).The difference in the adverse drug reactions in the two groups was not statistically significant (P >0.05).Conclusion: Compared with entecavir, pegylated interferon combined with entecavir in the treatment of hepatitis B shows better clinical effect and security, which is more worthy of clinical promotion.
